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Summary  
Plasmodium vivax and the related simian malarial parasite P. knowlesi use the DuffT blood group 
antigen as a receptor to invade human erythrocytes and region II of the parasite ligands for 
binding to this erythrocyte receptor. Here, we identify the peptide within the Duffy blood 
group antigen of human and rhesus erythrocytes to which the P. vivax and P. knowlesi ligands 
bind. Peptides from the NH2-terminal extracellular region of the Duffy antigen were tested for 
their ability to block the binding of erythrocytes to transfected Cos cells expressing on their 
surface region II of the Duffy-binding ligands. The binding site on the human Duffy antigen 
used by both the P. vivax and P. knowlesi l gands maps to a 35-amino acid region. A 34-amino 
acid peptide from the equivalent region of the rhesus Duffy antigen blocked the binding of 
P. vivax to human erythrocytes, although the P. vivax ligand expressed on Cos cells does not 
bind rhesus erythrocytes. The binding of the rhesus peptide, but not the rhesus erythrocyte, to 
the P. vivax ligand was explained by interference of carbohydrate with the binding process. 
Rhesus erythrocytes, treated with N-glycanase, bound specifically to P. vivax region II. Thus, 
the interaction of P. vivax ligand with human and rhesus erythrocytes appears to be mediated 
by a peptide-peptide interaction. Glycosylation of the rhesus Duffy antigen appears to block 
binding of the P. vivax ligand to rhesus erythrocytes. 
I nvasion of erythrocytes by Plasmodium merozoites i  a multistep rocess that requires a series of specific molec- 
ular interactions between the invading merozoite and the 
target erythrocyte. P vivax and the related simian malarial 
parasite, P. knowlesi, require interaction with the erythrocyte 
chemokine receptor, also known as the Duffy blood group 
antigen, to invade human erythrocytes (1-5). Duffy-nega- 
tive human erythrocytes, which lack the Duffy blood group 
antigen, are completely resistant to invasion by these para- 
sites. Although P. knowlesi is absolutely dependent on the 
Duffy blood group antigen for invasion of human erythro- 
cytes, P. knowlesi can efficiently invade rhesus erythrocytes 
by Duffy antigen-independent pathways (4). The erythro- 
cyte receptors for P. knowlesi involved in these Duffy antigen- 
independent invasion pathways are not known. 
The P. vivax and P. knowlesi ligands that bind to the 
Duffy blood group antigen contain a cysteine-rich domain 
that occurs in a superfamily of Plasmodium proteins that serve 
as host-binding ligands (6). These include ligands that bind 
erythrocytes during invasion (7, 8), as well as ligands that 
mediate binding of P. falciparum-infected rythrocytes to the 
endothelium (6, 9, 10). This cysteine-rich domain, referred 
to as region II, is found in the Duffy-binding proteins of 
P. vivax and P. knowlesi (the ti gene), in other erythrocyte- 
binding proteins of P. knowlesi (the [3 and y genes), and in 
the P. falciparum glycophorin A-binding protein EBA-175 
(11). When expressed in Cos cells, region II in the Duffy- 
binding ligands of P. vivax and P. knowlesi binds human 
Duffy-positive rythrocytes with the same specificity as the 
protein from which it derives (7). 
In this paper, we identify the epitope in the Duffy blood 
group antigen that blocks the binding of Duffy-positive 
human erythrocytes to P. vivax region II that is expressed on 
the surface of Cos cells. Sequence analysis suggests that the 
human and rhesus Duffy antigens contain multiple trans- 
membrane stretches with an ~64-amino acid hydrophilic 
region at the NH2 terminus that is extracellular (12). Here, 
we demonstrate hat a 35-amino acid peptide from this ex- 
tracellular portion of the human Duffy blood group antigen 
blocks the binding ofDuffy-positive erythrocytes to region 
II of the Duffy-binding proteins of P. vivax and P. knowlesi. 
We find that he same region of the rhesus Duffy antigen 
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also blocks binding of  P. vivax region II to Duffy-positive 
human erythrocytes, although rhesus erythrocytes do not 
bind to P. vivax region II. Rhesus erythrocytes, however, can 
bind P. vivax region II after treatment with N-glycanase, 
which removes N-l inked sugars, indicating that carbohy- 
drates block the receptor on rhesus erythrocytes for P. viva,~c. 
These studies uggest that the P. vivax ligand can bind the pep- 
tide backbones of both the human and rhesus Duffy antigens. 
Materials and Methods 
Recombinant Plasmids for Surface Expression its Cos7 Cells. The plas- 
mid constructs used to express region II of the P. vivax Dully- 
binding protein (pHVDP,22), the P. knowlesi Dully-binding pro- 
tein (pHKADP,22), the P. knowlesi [3 protein (pHKBDR22), and 
P. falciparum EBA-175 (EBA-175 RII) on the Cos cell surface 
have been described previously (7, 8). Each of these constructs 
contains DNA sequences encoding region II of the parasite 
ligands fused with the signal sequence and transmembrane s g- 
ment of herpes implex virus glycoprotein D (HSV gD). The fu- 
sion proteins are targeted to the Cos cell surface by the signal se- 
quence of HSV gD and are anchored to the surface by the 
transmembrane s gment. These expression plasmids contain a 
SV40 origin of replication that allows replication in Cos7 cells, as 
well as a Rous sarcoma virus long terminal repeat hat serves as a 
promoter for expression i Cos7 cells (13). 
Cell Culture and Tra,4~ection f Cos7 Cells. Cos7 cells (CRL 1651; 
American Type Culture Collection, Rockville, MD) were cul- 
tured in DMEM with 10% heat-inactivated FCS (both from 
GIBCO BP, L, Gaithersburg, MD) in a humidified CO2 (5%) in- 
cubator at 37~ Fresh monolayers of Cos7 cells were transfected 
in 3.5-cm-diameter wells with 5 txg ofplasmid DNA by the cal- 
cium phosphate precipitation method, as described earlier (7). 
Cells were washed three times in PBS 12-16 h after transfection. 
Transfection efficiencies were determined by inmmnofluores- 
cence assays 48-60 h after transfection, as described earlier (7). 
Ascites containing the n~b DL6 (kindly provided by Drs. Gary 
Cohen and Roselyn Eisenberg, University of Pennsylvania, Phil- 
adelphia, PA) that reacts against amino acids 272-279 of the ma- 
ture HSV gD protein were used as the primary antibody in the 
inmmnofluorescence assays as described earlier (13). 
Erythrocyte-binding Assays. Cos7 cells were transfected in 3.5- 
cm-diam wells and used for erythrocyte-binding assays 40-60 h 
after transfection, asdescribed earlier (7). Briefly, 100/xl of a 10% 
erythrocyte suspension was added to 0.9 ml of media in wells 
containing transfected cells. The plates were swirled to nfix the 
erythrocytes well, and the rythrocytes were allowed to settle tbr 
2 h at 37~ Nonadherent erythrocytes were removed by wash- 
ing the Cos7 cells three times with PBS, and the number oftrans- 
fected Cos7 cells with rosettes of erythrocytes was scored in 20 
fields at a magnification of 40 using an inverted microscope. 
To study the ability of peptides froln the Duffy antigen to 
inhibit erythrocyte binding, transfected Cos cells were preincu- 
bated for 1 h in a 5% CO 2 incubator at 37~ in 0.9 ml of com- 
plete DMEM with 10% FCS containing different concentrations 
(0-100 ixM) of peptides. Human or rhesus erythrocytes (100 txl) 
at a hematocrit of 10% were added to wells containing different 
concentrations of the peptides and were allowed to bind for 2 h at 
37~ in a 5% CO 2 incubator. Nonadherent erythrocytes were re- 
moved by washing the Cos7 cells three times with PBS, and the 
number of rosettes was scored in 20 fields viewed at amagnifica- 
tion of 40() using an inverted nficroscope. Inhibition curves were 
drawn for three independent experiments and used to determine 
concentrations for 50% inhibition. 
To study the ability of the chemokine MGSA (melanoma 
growth-stimulating activity) in inhibiting binding, erythrocytes 
were preincubated in media containing different concentrations 
of MGSA (0-1,000 nM) for 1 h at room temperature b fore they 
were used in erythrocyte-binding assays, as described earlier (7). 
Erythrocytes and Pretreatments witll Enzymes. Blood was collected 
in 10% citrate phosphate dextrose (Baxter, Deerfield, IL) and 
stored at 4~ for up to 4 wk. Standard blood banking methods 
using two antisera (anti-Fya and anti-Fyb) were used to deter- 
mine the Duffy phenotypes. Duffy-positive rythrocytes u ed in 
the binding assays had the Fy(a+b +) phenotype. Erythrocytes 
were washed three times in RPMI 1640 (GIBCO BP, L) and re- 
suspended to a hematocrit of 10% in RPM[ 1640 for use in the 
erythrocyte-binding assays. Washed human and rhesus erythro- 
cytes were treated with neuraminidase, as described earlier (14). 
Human, rhesus, and squirrel monkey erythrocytes were deglyco- 
sylated with the N-glycanase peptide-N-glycosidase F from Fla- 
vobacterium e, ingosepticum (Oxford Glycosystems, Oxford, U.K.). 
Washed erythrocytes (10(I ~1) were incubated with mixing for 
1 h at 37~ in 500 I*1 of PBS containing 10 U of N-glycanase and 
reaction buffer supplied by the manufacturer. The erythrocytes 
were washed extensively in PBS to remove the enzyme and stop 
the deglycosylation. 
Pepticle Synthesis. Peptides were synthesized using an auto- 
mated synthesizer, as described earlier (15). Mass pectrophoto- 
metric and analytical reverse-phase HPLC analyses and amino 
acid composition were performed to confirm the purity and se- 
quence of the synthetic peptides. In some cases, protein sequence 
analysis was also performed to check the sequence of the peptides. 
Results and Discussion 
Region II, the 5' cysteine-rich region of the P. vivax 
Duffy antigen-binding protein, has been shown to possess 
erythrocyte-binding properties (7). Transfected Cos cells 
expressing P. vivax region II on the cell surface bind Duff-y- 
positive, but not Duffy-negative, human erythrocytes (7). 
Here, we have used the Cos cell-binding assay to identify 
the binding site on the human Duffy antigen that is used in 
this interaction. A 35-amino acid peptide (HPEP35) from 
the NH2-terminal extracellular domain of  the human i)uffT 
antigen (Fig. 1 a) was tested for its ability to inhibit binding 
of  P. vivax region II to human erythrocytes in the Cos cell-  
binding assay. HPEP35 was chosen because it is recognized 
by anti-Fy6 (Chaudhuri, A., unpublished ata), an mAb to 
the human Dully antigen that can block erythrocyte inva- 
sion by P. vivax in vitro (16). To test the ability of  HPEP35 
to inhibit binding of human erythrocytes to P. vivax region 
II, Cos cell-binding assays were performed in the presence of 
increasing concentrations ((i)-100 b~M) of HPEP35. Fig. 2 
shows the inhibition curve from one such experiment. 
HPEP35 inhibits the binding of Duffy-positive human 
erythrocytes to Cos cells expressing P. vivax region II with 
50% inhibition at a concentration of 2.9 -+ /.4 txM (Table 1). 
Three smaller peptides from the 35-anfino acid region of 
HPEP35 were also tested in the inhibition assays (Fig. 1 b). 
The smaller peptides (HPEP13, HPEP22, and HPEP3850) 
had no effect on the binding of human erythrocytes to re- 
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HPEP35 
RHPEP34 
AELSPSTENSSQLDFEDVWNSSYGVNDSFPDGDYD 
AELSPSTQNSSQL_NSDLWNFSYDGNDSFPDVDYD 
b HPEP35 AEL SPSTENSSQLDFEDVWNS YGVNDSF PDGDYD 
HPEPI 3 AELSPSTENSSQL 
H PE P22 DFEDVWNS SYGVNDS F PDGDYD 
HPEP3850 PSTENSSQLDFEDVWNS YGVNDS 
Figure 1. Peptides from the NH2-terminal, extracellular segment of the 
human and rhesus Duffy blood group antigens. (b) Amino acid sequence 
ofpeptides from the human Duffy antigen (HPEP35, HPEP13, HPEP22, 
and HPEP3850). (a) Comparison of the rhesus peptide RHPEP34 and 
the human peptide HPEP35. 
gion II of  the P. vivax protein at concentrations up to 100 
b~M. HPEP35 also inhibits the binding of  human erythro- 
cytes to region II o f  the P. knowlesi Duffy antigen-binding 
protein with 50% inhibition at a concentration of  4.9 + 2.3 
~M. It thus appears that the P. vivax and P. knowlesi ligands 
bind the same site on the human Duffy blood group anti- 
gen. In addition, HPEP35 also inhibits the binding of  
rhesus erythrocytes to region II of  the P. knowlesi Duffy an- 
t igen-binding protein (the ot gene), suggesting that the 
same site within the parasite domain is used for binding to 
both human and rhesus Duffy blood group antigens. 
To rule out the possibility that the inhibition of  binding 
observed with HPEP35 is a nonspecific effect, we tested 
the ability of  HPEP35 to inhibit the binding of  erythro- 
cytes to region II of  P. falciparum EBA-175 and region II of 
the P. knowlesi f3 protein, neither of  which binds the Duffy 
antigen. Region II of  EBA-175 binds sialic acid residues in 
the context of  the glycophorin A peptide backbone, and 
region II of  the P. knowlesi [3 protein binds an as-yet-uniden- 
tified receptor on rhesus erythrocytes. HPEP35 had no ef- 
100 - 
8O 
60 
40 t -  
_,- 
20 
0 i t i i 
0.1 I~M 1 pM 10 I~M 100 pM 
Peptide (HPEP35) Concentrat ion 
Figure 2. Inhibition oferythrocyte binding to P. vivax region II with 
the peptide HPEP35. An inhibition curve for one experiment in which 
the peptide HPEP35 is used to inhibit the binding of Duffy-positive hu- 
man erythrocytes to transfected Cos cells expressing P. vivax re ion II is 
shown. The concentration for 50% inhibition of erythrocyte binding was 
determined for each experiment from the inhibition curve as shown. 
Table 1. Inhibition of Erythrocyte Binding to Transfected Cos 
Cells Expressing Region H Using Peptides fiom the Human 
(HPEP35) and Rhesus (RHPEP34) Duffy Antigens* 
50% inhibition 
concentration 
Region II expressed (No. of 
on Cos cell surface Erythrocytes Mean _+ SD studies) 
A Inhibition oferythrocyte binding with HPEP35 
P. vivax Human Fy(a+b +) 2.9 -4- 1.4 I~M (3) 
P. knowlesi oL Human Fy(a+b +) 4.1 • 2.7 b~M (3) 
P. knowlesi (x Rhesus 13.1 - 6.0 ~M (3) 
P. knowlesi f3 Rhesus >100 IxM (2) 
P. falciparum 
EBA-175 Human Fy(a+b +) >100 I~M (2) 
B Inhibition oferythrocyte binding with RHPEP34 
P. vivax Human Fy(a+b +) 2.1 - 2.1 I.LM (3) 
P. knowlesi eL Human Fy(a+b +) 5.5 -+ 3.9 b~M (3) 
P. knowlesi (x Rhesus 4.9 + 2.3 ~M (3) 
P. knowlesi f3 Rhesus >100 I,,tM (2) 
P. falciparum 
EBA-175 Human Fy(a+b +) >100 [,*M (2) 
*Average concentrations (-+ SD) for the peptides HPEP35 (Fig. 1 b) 
and RHPEP34 (Fig. 1 a) at which 50%} inhibition of binding is achieved 
are shown. Inhibition curves from tw  to three independent xperi- 
ments were used to etermine the average concentrations at which 50% 
inhibition is achieved. The highest concentration at which the peptides 
were tested was 100 t~M. For cases where the average concentrations 
for 5{)% inhibition is reported as >100 p~M, the inhibition was <5% at 
the highest peptide concentration used (100 IxM). Numbers in brackets 
(No. of studies) show the number of independent experiments used for 
the determination fthe 50% inhibition concentrations. 
fect on the binding of  human erythrocytes to region II of 
EBA-175 or the binding of  rhesus erythrocytes to region II 
of the P. knowlesi [3 protein at concentrations up to 100 btM 
(Table 1). 
The amino acid differences between the human and 
rhesus Duffy antigens in the 35-amino acid region that has 
been identified as the binding site are shown in Fig. 1 a. 
Compared with the human Duffy antigen, eight amino 
acid substitutions and a single amino acid deletion are evi- 
dent in the rhesus sequence in this region (17). To deter- 
mine whether the corresponding 34-amino acid region of  
the rhesus Duffy antigen (RHPEP34) serves as the binding 
site for the P. knowlesi Duffy antigen-binding protein, the 
ability of  RHPEP34 to inhibit erythrocyte binding in Cos 
cell assays was tested (Table 1 B). RHPEP34 inhibits bind- 
ing of  rhesus as well as human erythrocytes to region II 
o f  the P. knowlesi Duffy-binding protein, indicating that 
RHPEP34 indeed serves as the binding site on the rhesus 
Duffy antigen for the P. knowlesi ligand. As a test for speci- 
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Table 2. Attachment of N-Glycanase-treated Rhesus Erythrocytes 
to Region II of the P. vivax Duffy-binding Ligand* 
Erythrocytes Treatment Binding 
Rhesus None - 
Rhesus N:glycanase + 
Rhesus Neuraminidase - 
Squirrel monkey None 
Squirrel monkey N-glycanase + 
Human Fy(a+b +) None + 
Human Fy(a+b +) N-glycanase + 
Human Fy(a-b ) None 
Human Fy(a-b-) N-glycanase - 
*Transfected Cos cells expressing re ion II of the P. vivax Duffy-bind- 
ing ligand were tested for binding to rhesus and human erythrocytes. 
Binding is reported as negative (-) when no rosettes were seen in the 
entire well. Where binding is reported as positive (+), ~100-200 ro- 
settes are seen in 20 fields viewed at a magnification f 40. In each case, 
immunofluorescence assays were perfomaed to ensure that P. vivax re- 
gion I1 was expressed on the Cos cell surface. Transfection efficiencies 
were in the range of 2-5%. 
ficity, we confirmed that 1LHPEP34 does not inhibit the 
binding of  human erythrocytes to region II of  P. falciparum 
EBA-175 or the binding of  rhesus erythrocytes to region 
II of  the P. knowlesi [3 protein, neither of  which binds the 
Duffy antigen (Table 1 /3). We also tested the ability of  
R, HPEP34 to inhibit the binding of  human erythrocytes to 
region II of  the P. vivax Duffy antigen-binding protein. 
Since P. vivax region II does not bind rhesus erythrocytes, 
we expected that R, HPEP34, a peptide from the rhesus 
Duff-y antigen, would not inhibit the binding of  human 
erythrocytes to P. vivax region II. Unexpectedly, we found 
that RHPEP34 inhibits the binding of  human Duffy-posi- 
tive erythrocytes to P. vivax region II with 50% inhibition 
at concentrations of  2.1 -+ 2.1 I~M (Table 1 B). Thus, it 
appears that although P. vivax region II does not bind the 
Duffy antigen on rhesus erythrocytes, a peptide from the 
rhesus Duffy antigen can block the binding of human eryth- 
rocytes to P. vivax region II. 
One possible reason for this anomalous result with the 
synthetic peptide is that carbohydrates on the rhesus, but 
not the human, Duffy blood group antigen may block ac- 
cess of  the parasite ligand to the peptide backbone of the 
receptor molecule. It has been demonstrated that the hu- 
man Duffy blood group antigen has asparagine-linked gly- 
cosylation (18, 19). Presumably, the rhesus Duffy antigen 
also has asparagine-linked glycosylation, since it contains 
the same amino acid sequence signals NXS/T  as the hu- 
man sequence (17). To determine whether glycosylation of  
the rhesus Duffy blood group antigen influences binding, 
we studied the binding of  normal and N-glycanase-treated 
rhesus erythrocytes to P. vivax region II. Whereas normal 
Table 3. Inhibition by MGSA of the Attachment of 
N-Glycanase--treated Rhesus Erythrocytes to Region 1I qf the 
P. vivax Duffy-binding Ligand* 
Region II 50% inhibition 
expressed on concentration 
Cos cell surface Erythrocytes Treatment (MGSA) 
P. knowlesi oL Rhesus None 5 nM 
P. vivax Rhesus N-glycanase 5 nM, 6 nM 
P. knowlesi f3 Rhesus N-glycanase >1 IxM 
*Normal and N--glycanase-treated rh sus erythrocytes were preincu- 
bated with different concentrations (0, 0.1,1, 10, 100, and 1,000 nM) 
of the chemokine MGSA (melanoma growth~timulating activity) and 
used in binding assays with transfected Cos cells expressing P. vivax re- 
gion II. Numbers represent concentrations at which 50% inhibition of 
binding was achieved. Two separate experiments were performed with 
P. vivax region II and N-glycanase-treated rhesus erythrocytes. 
rhesus erythrocytes do not bind P. vivax region II, N-gly- 
canase-treated rhesus erythrocytes bind the P. vivax ligand 
(Table 2). This indicates that, despite the differences in 
amino acid sequences, P. vivax can bind the peptide back- 
bones of  both the human and rhesus Duffy antigens. This 
explains why P, HPEP34, a peptide derived from the rhesus 
Duffy antigen, inhibits the binding of human erythrocytes 
to P. vivax region II. 
Erythrocytes from a new world monkey, the squirrel 
monkey (Saimiri sciureus), do not bind the P. vivax Duffy- 
binding protein (5), although they express the Duffy blood 
group antigen (16, 17). We found that the squirrel monkey 
erythrocytes fail to bind to Cos cells expressing P. vivax re- 
gion II, but do bind to Cos cells expressing the P. knowlesi 
Duffy binding protein (oL gene) region II (7). N-glycanase- 
treated squirrel monkey erythrocytes, like rhesus erythro- 
cytes, bind to Cos cells expressing P. vivax region II (Table 2), 
indicating that carbohydrates on the Duffy blood group an- 
tigen of squirrel monkey erythrocytes also block its binding 
to the P. vivax Duffy-binding protein. 
It can be argued that enzymatic treatment with N-glyca- 
nase reduces the negative surface charge density on erythro- 
cytes and leads to nonspecific binding interactions. Another 
possibility that must be considered is that N-glycanase treat- 
ment may create a novel binding epitope independent of 
the Duffy blood group antigen. To test these possibilities, 
the following experiments were performed. Since sialic 
acid residues are the most important source of negative 
charge on the erythrocyte surface, neuraminidase-treated 
rhesus erythrocytes were tested for binding to P. vivax re- 
gion II. Neuraminidase-treated rhesus erythrocytes did not 
bind P. vivax region II (Table 2). In the same experiment, 
neuraminidase-treated human erythrocytes did not bind re- 
gion II of  EBA-175, which requires ialic acid for binding, 
indicating that sialic acid was removed from the erythro- 
cytes. Reduction of  negative charge on the surface cannot, 
therefore, account for the binding of  N-glycanase-treated 
1534 Plasmodium vivax-and P. knowlesi-binding S tes on Duffy Antigen 
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rhesus erythrocytes to P. vivax region II. It was also found 
that N-glycanase-treated, Duffy-negative human erythro- 
cytes do not bind P. vivax region II (Table 2). This rules 
out the possibility that N-glycanase treatment may create a 
novel epitope that binds P. vivax region II. 
We have previously shown that the chemokine, MGSA, 
binds the Duffy blood group antigen and can be used to in- 
hibit the binding ofP. vivax region II to Duff-y-positive hu- 
man erythrocytes (3, 7). MGSA also binds the rhesus Duffy 
antigen (Horuk, R., unpublished ata). Indeed, MGSA in- 
hibits the binding of rhesus erythrocytes to Cos cells ex- 
pressing region II of the P. knowlesi Duffy-binding ligand 
(the (x gene; Table 3). To confirm that P. vivax region II 
binds the peptide backbone of the deglycosylated rhesus 
Duffy blood group antigen, we tested whether MGSA 
could inhibit the binding of N-glycanase-treated rhesus 
erythrocytes to P. vivax region II. MGSA inhibits the bind- 
ing of N-glycanase--treated rhesus erythrocytes to region II 
of the P. vivax Duffy antigen-b, inding protein, with 50% 
inhibition at nanomolar concentrations (Table 3). Inhibition 
of erythrocyte binding indicates that MGSA and P. vivax 
region II bind the same molecule on N-glycanase-treated 
rhesus erythrocytes, namely the deglycosylated rhesus Duffy 
antigen. Chemokine and the P. vivax Duffy-binding pro- 
tein, however, do not recognize the same epitope because 
the 35 met from the human Duffy antigen does not block 
binding of chemokines to human erythrocytes (Horuk, P,., 
unpublished ata). 
One puzzle is why P. vivax infects squirrel monkeys, al- 
though squirrel monkey erythrocytes do not bind P. vivax 
Duffy-binding protein (5) and also do not bind to Cos cells 
expressing P. vivax region II (this study). Squirrel monkey 
erythrocytes do contain the r ticulocyte receptor to which 
the P. vivax reticulocyte-binding proteins bind (20). Bind- 
ing to the reticulocyte r ceptors i responsible for the pref- 
erential invasion freticulocytes byP. vivax (20). These in- 
teractions are not, however, sufficient for invasion. For 
example, Duffy-negative human erythrocytes that carry the 
reticulocyte receptor are not invaded by P. vivax. We can 
speculate that the Duffy blood group antigen on squirrel 
monkey erythrocytes, despite not being ideal for binding 
because of carbohydrate modifications, till function in in- 
vasion. The erythrocyte-binding assays used may not be 
sensitive enough to detect this weaker interaction. How 
does one then explain the refractoriness of rhesus erythro- 
cytes to invasion by P. vivax when P. vivax region II binds 
N-glycanase-treated rhesus erythrocytes? Rhesus erythrocytes 
are known to lack the reticulocyte receptor (20) for the 
P. vivax reticulocyte-binding proteins. It is possible that, 
like the Duffy antigen, the reticulocyte receptor is also ab- 
solutely required for invasion. Their absence on rhesus eryth- 
rocytes may be the reason for their refractoriness to P. vivax. 
Differences exist between the nature of the receptor- 
binding specificities for region II of P. falciparum EBA-175 
and of the P. vivax Duffy-binding ligand. Whereas P. falci- 
parum EBA-175 requires both sialic acid and the peptide 
backbone of glycophorin A (8, 14), the P. vivax Duffy- 
binding ligand requires only the peptide backbone of the 
Duffy blood group antigen. Both tryptic fragments of gly- 
cophorin A containing amino acids 1-64 and the 35-amino 
acid synthetic peptide from the extracellular domain of the 
Duffy antigen inhibit binding of erythrocytes to their re- 
spective ligands with 50% inhibition at concentrations of
",5 I,~M (reference 8, and this paper). Thus, peptides de- 
rived from the Duffy antigen (in the absence of any carbo- 
hydrates) appear to effectively inhibit erythrocyte binding 
by the P. vivax ligand. Furthermore, rhesus erythrocytes 
can bind P. vivax region II after treatment with N-glyca- 
nase. We conclude that the receptor-ligand interactions 
that mediate erythrocyte invasion differ in the protein to 
which they bind and in the requirement for carbohydrate. 
The receptor for P. falciparum EBA-175 consists of both 
carbohydrate and the peptide backbone of glycophorin A; 
the P. vivax Duffy-binding ligand interacts only with the 
peptide backbone of the receptor molecule. 
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